Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

34.21
Delayed Data
As of Feb 12
 +0.09 / +0.26%
Today’s Change
30.30
Today|||52-Week Range
46.24
-20.74%
Year-to-Date

Today’s Trading

Previous close34.12
Today’s open34.51
Day’s range33.87 - 34.94
Volume1,385,900
Average volume (3 months)946,828
Market cap$2.4B
Dividend yield--
Data as of 4:00pm ET, 02/12/2016

Growth & Valuation

Earnings growth (last year)-52.00%
Earnings growth (this year)+14.22%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)-7.08%
P/E ratio25.7
Price/Sales3.50
Price/Book3.56

Competitors

 Today’s
change
Today’s
% change
IPXLImpax Laboratories I...+0.16+0.52%
HZNPHorizon Pharma PLC+0.89+5.52%
AKRXAkorn Inc+1.30+5.74%
RAREUltragenyx Pharmaceu...+1.33+2.49%
Data as of 4:00pm ET, 02/12/2016

Financials

Next reporting dateMay 3, 2016
EPS forecast (this quarter)$0.38
Annual revenue (last year)$723.1M
Annual profit (last year)$80.2M
Net profit margin11.09%

Profile

Sector
Health Technology
Industry
Biotechnology
President &
Chief Executive Officer
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts

Partner Offers